SK283821B6 - Farmaceutické preparáty na inhibíciu tumornekrózafaktora - Google Patents
Farmaceutické preparáty na inhibíciu tumornekrózafaktora Download PDFInfo
- Publication number
- SK283821B6 SK283821B6 SK1073-97A SK107397A SK283821B6 SK 283821 B6 SK283821 B6 SK 283821B6 SK 107397 A SK107397 A SK 107397A SK 283821 B6 SK283821 B6 SK 283821B6
- Authority
- SK
- Slovakia
- Prior art keywords
- treatment
- activation
- manufacture
- carbon atoms
- oxazolidinones
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19505516 | 1995-02-10 | ||
PCT/DE1996/000257 WO1996024350A1 (de) | 1995-02-10 | 1996-02-09 | Pharmazeutische präparate zur tnf-inhibition |
Publications (2)
Publication Number | Publication Date |
---|---|
SK107397A3 SK107397A3 (en) | 1997-12-10 |
SK283821B6 true SK283821B6 (sk) | 2004-02-03 |
Family
ID=7754327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1073-97A SK283821B6 (sk) | 1995-02-10 | 1996-02-09 | Farmaceutické preparáty na inhibíciu tumornekrózafaktora |
Country Status (14)
Country | Link |
---|---|
US (1) | US6117895A (cs) |
EP (1) | EP0804192A1 (cs) |
JP (1) | JPH11500110A (cs) |
KR (1) | KR19980702116A (cs) |
CN (1) | CN1173818A (cs) |
AU (1) | AU706159B2 (cs) |
CZ (1) | CZ290671B6 (cs) |
FI (1) | FI973277A (cs) |
HU (1) | HUP9702408A3 (cs) |
IL (1) | IL117090A (cs) |
MX (1) | MX9706086A (cs) |
SK (1) | SK283821B6 (cs) |
WO (1) | WO1996024350A1 (cs) |
ZA (1) | ZA961081B (cs) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8747998A (en) * | 1997-08-21 | 1999-03-16 | Takeda Chemical Industries Ltd. | Anti-inflammatory agent |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
TW200732313A (en) * | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2413935A1 (de) * | 1974-03-20 | 1975-10-16 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone |
DE2541855A1 (de) * | 1975-09-18 | 1977-03-31 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone ii |
FR2358155A1 (fr) * | 1976-07-15 | 1978-02-10 | Lapinet Eugene | Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses |
DE2655369A1 (de) * | 1976-12-03 | 1978-06-08 | Schering Ag | 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung |
US5783591A (en) * | 1984-10-19 | 1998-07-21 | Schering Aktiengesellschaft | Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation |
DE3438839A1 (de) * | 1984-10-19 | 1986-04-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Pharmazeutische praeparate |
US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
DE3639225A1 (de) * | 1986-11-14 | 1988-05-19 | Schering Ag | Verwendung von 5-(subst. phenyl)-oxazolidinonderiaten als psychopharmaka |
KR920702621A (ko) * | 1989-06-13 | 1992-10-06 | 스튜어트 알. 슈터 | 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제 |
DE69128627T2 (de) * | 1990-08-03 | 1998-07-02 | Smithkline Beecham Corp | Tnf-inhibitoren |
PT100441A (pt) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
US5227369A (en) * | 1991-07-11 | 1993-07-13 | The Regents Of The University Of California | Compositions and methods for inhibiting leukocyte adhesion to cns myelin |
GB9204808D0 (en) * | 1992-03-04 | 1992-04-15 | Rhone Poulenc Rorer Ltd | Novel compositions of matter |
US5264437A (en) * | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
US5672622A (en) * | 1994-04-21 | 1997-09-30 | Berlex Laboratories, Inc. | Treatment of multiple sclerosis |
-
1996
- 1996-02-09 JP JP8523903A patent/JPH11500110A/ja not_active Ceased
- 1996-02-09 HU HU9702408A patent/HUP9702408A3/hu unknown
- 1996-02-09 AU AU47122/96A patent/AU706159B2/en not_active Ceased
- 1996-02-09 MX MX9706086A patent/MX9706086A/es not_active IP Right Cessation
- 1996-02-09 IL IL11709096A patent/IL117090A/xx not_active IP Right Cessation
- 1996-02-09 SK SK1073-97A patent/SK283821B6/sk unknown
- 1996-02-09 WO PCT/DE1996/000257 patent/WO1996024350A1/de not_active Application Discontinuation
- 1996-02-09 ZA ZA961081A patent/ZA961081B/xx unknown
- 1996-02-09 CN CN96191868A patent/CN1173818A/zh active Pending
- 1996-02-09 EP EP96902870A patent/EP0804192A1/de not_active Withdrawn
- 1996-02-09 CZ CZ19972513A patent/CZ290671B6/cs not_active IP Right Cessation
- 1996-02-10 KR KR1019970705511A patent/KR19980702116A/ko not_active Application Discontinuation
- 1996-07-18 US US08/683,467 patent/US6117895A/en not_active Expired - Fee Related
-
1997
- 1997-08-08 FI FI973277A patent/FI973277A/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU4712296A (en) | 1996-08-27 |
HUP9702408A2 (hu) | 1998-05-28 |
FI973277A0 (fi) | 1997-08-08 |
CZ290671B6 (cs) | 2002-09-11 |
EP0804192A1 (de) | 1997-11-05 |
IL117090A (en) | 2000-07-26 |
CZ251397A3 (en) | 1997-12-17 |
JPH11500110A (ja) | 1999-01-06 |
HUP9702408A3 (en) | 2000-08-28 |
WO1996024350A1 (de) | 1996-08-15 |
SK107397A3 (en) | 1997-12-10 |
MX9706086A (es) | 1997-10-31 |
AU706159B2 (en) | 1999-06-10 |
FI973277A (fi) | 1997-08-08 |
ZA961081B (en) | 1996-10-15 |
US6117895A (en) | 2000-09-12 |
KR19980702116A (ko) | 1998-07-15 |
CN1173818A (zh) | 1998-02-18 |
IL117090A0 (en) | 1996-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Denton et al. | Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy | |
EP2457567A1 (en) | Agent having neurotrophic factor-like activity | |
DK161325B (da) | Analogifremgangsmaade til fremstilling af imidazooe4,5-caa-pyridinderivater | |
US6387936B1 (en) | Combinations of riluzole and levodopa for the treatment of Parkinson's disease | |
Myslobodsky et al. | Amygdaloid kindling and the GABA system | |
AU2017222406B2 (en) | Methods of treating diseases characterised by vasoconstriction | |
WO2015051327A1 (en) | Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells | |
AU752192B2 (en) | The use of valproic acid analog for the treatment and prevention of migraine and affective illness | |
SK283821B6 (sk) | Farmaceutické preparáty na inhibíciu tumornekrózafaktora | |
CA2711743A1 (en) | Quinazolinone derivatives for treating or preventing skeletal muscle fibrosis | |
CA2212440C (en) | Pharmaceutical preparations for tnf inhibition | |
US4977172A (en) | Method of treating the symptoms of cognitive decline in an elderly patient employing (S)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)-methyl]-2-oxazolidinone | |
CA2074039C (en) | Antihypertensive combination | |
US5075288A (en) | Somnogenic fragment of interleukin-1β | |
WO2022098157A1 (ko) | 히드로플루메티아지드를 유효성분으로 포함하는 TNF-α 관련 질환 예방 또는 치료용 조성물 | |
JP6447496B2 (ja) | 多発性硬化症の治療剤又は予防剤 | |
JP2010111581A (ja) | ドーパミンd2様受容体アゴニストを有効成分とする医薬及びスクリーニング方法 | |
US20220288081A1 (en) | Treatment of excitotoxicity-related conditions | |
WO2014106967A1 (ko) | 뉴로펩티드 y를 유효성분으로 포함하는 골다공증의 예방 또는 치료용 약학적 조성물 | |
CA3155209A1 (en) | Use of imidazopyrimidine or imidazotriazine compounds for prevention, alleviation, or treatment of cognitive disorders, or for improving cognitive function | |
KR20050109952A (ko) | 연골발생 분화를 유도하기 위한 비면역억제성 피페콜린산유도체의 용도 | |
KR100627750B1 (ko) | 암톨메틴 구아실의 장내 염증용 소염제 제조를 위한 용도 | |
CN116942686A (zh) | 红景天苷在制备治疗心脏离子通道疾病的药物中的用途 | |
AU3266099A (en) | Inflammatory cell inhibitors | |
WO1988007368A2 (fr) | Composition medicamenteuse pour le traitement et la prevention de maladies dues a une cytotoxicite a mediation cellulaire, renfermant au moins un derive de la pyridine comme principe actif |